Arovella Therapeutics Ltd
E4NA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,683.40 | 55.00 | 0.64% |
| CAC 40 | 7,891.68 | 14.72 | -0.19% |
| DAX 40 | 21,585.93 | 80.23 | 0.37% |
| Dow JONES (US) | 44,680.08 | 258.17 | 0.58% |
| FTSE 100 | 8,623.29 | 52.52 | 0.61% |
| HKSE | 20,597.09 | 192.87 | -0.93% |
| NASDAQ | 19,647.13 | 6.89 | -0.04% |
| Nikkei 225 | 38,831.48 | 33.11 | 0.09% |
| NZX 50 Index | 12,844.59 | 60.45 | -0.47% |
| S&P 500 | 6,045.34 | 7.46 | 0.12% |
| S&P/ASX 200 | 8,416.90 | 37.50 | 0.45% |
| SSE Composite Index | 3,229.49 | 21.11 | -0.65% |